CAI
Caris Life Sciences, Inc. Common StockCAI
CAI
About: Caris Life Sciences Inc is a patient-centric, next-generation AI TechBio company. It develop and commercialize solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale.
–
Funds holding %
of 7,335 funds
0
Analysts bullish %
of 6 analysts
Fund manager confidence
Research analyst outlook
6 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$31
3%
upside
Avg. target
$32
7%
upside
High target
$34
13%
upside
6 analyst ratings
6 positive
100%
0 neutral
0%
0 negative
0%
Evercore ISI Group Vijay Kumar | 9%upside $33 | Outperform Initiated | 15 Jul 2025 |
TD Cowen Dan Brennan | 6%upside $32 | Buy Initiated | 14 Jul 2025 |
Guggenheim Subbu Nambi | 6%upside $32 | Buy Initiated | 14 Jul 2025 |
Wolfe Research Doug Schenkel | 6%upside $32 | Outperform Initiated | 14 Jul 2025 |
Citigroup Patrick Donnelly | 13%upside $34 | Buy Initiated | 14 Jul 2025 |
Financial journalist opinion
Based on 4 articles about CAI published over the past 30 days
Neutral
PRNewsWire
5 days ago
Caris Life Sciences Publishes Study Showing AI Signature-positive Breast Cancer Patients Live Almost Twice as Long as AI-negative Patients When Treated with a Checkpoint Inhibitor
Groundbreaking study in Nature Communications highlights AI's role in transforming immunotherapy decisions and precision oncology IRVING, Texas , Aug. 6, 2025 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, has published a new study in Communications Medicine, a Nature portfolio journal, demonstrating that Caris' AI-based image analysis model has the potential to more accurately predict cancer biomarkers and patient survival than the conventional companion diagnostic (CDx) methods. By analyzing hematoxylin and eosin (H&E) images, the study demonstrated that Caris' AI model can improve the assessment of critical cancer biomarkers and impact patient survival outcomes in breast and colorectal cancers.
Neutral
PRNewsWire
6 days ago
Caris Life Sciences Publishes Study Showing its Multi-Layer AI-Based Tissue of Origin Predictions are Best-in-Class and Identify when Patients have been Misdiagnosed
Caris GPSai™ utilizes deep learning to significantly improve diagnostic accuracy for cancers of unknown primary and misclassified tumors IRVING, Texas , Aug. 5, 2025 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, recently published a study on the development and validation of Caris' latest version of Caris GPSai™ in AACR's Cancer Research Communications Journal. Caris GPSai is a clinically validated deep learning multi-layer AI that leverages comprehensive whole exome and whole transcriptome sequencing (WES/WTS) to significantly improve diagnostic accuracy for cancers of unknown primary (CUP) and identify patients who have potentially misdiagnosed tumors.
Neutral
PRNewsWire
2 weeks ago
Caris Life Sciences to Report Second Quarter 2025 Financial Results on August 12, 2025
IRVING, Texas , July 23, 2025 /PRNewswire/ -- Caris Life Sciences ® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced it will report second quarter 2025 financial results on Tuesday, August 12, 2025. Caris Life Sciences will host a conference call and live webcast at 3:30 p.m.
Neutral
PRNewsWire
2 weeks ago
Caris Life Sciences Validates and Extends Findings on Tumor-Infiltrating Clonal Hematopoiesis
Validation was shared via a Letter to the Editor in the New England Journal of Medicine IRVING, Texas , July 22, 2025 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, published original data in the New England Journal of Medicine independently validating recent findings on tumor-infiltrating clonal hematopoiesis (TI-CH), and further reinforcing its leadership in precision oncology. As a champion of scientific collaboration, Caris appreciated the opportunity to validate a recent study published in the New England Journal of Medicine, which brought attention to the clinical challenge of TI-CH—blood-derived mutations that infiltrate tumor tissue and are often misinterpreted as tumor-specific mutations.
Neutral
PRNewsWire
1 month ago
Caris Life Sciences Announces New Study Demonstrating the Power and Clinical Utility of its Caris Assure® Blood-Based Assay for Multi-Cancer Early Detection, Minimal Residual Disease and Therapy Selection
Scientific Reports study validates the first multifunctional, AI-enabled blood-based assay to offer diagnostic, prognostic and predictive utility in a single assay. IRVING, Texas , July 8, 2025 /PRNewswire/ -- Caris Life Sciences ® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, announced a landmark study published in Scientific Reports, a Nature journal, demonstrating the accuracy and clinical utility of the Caris Assure® blood-based biopsy assay across the cancer continuum.
Positive
Seeking Alpha
1 month ago
U.S. IPO Weekly Recap: Sizable Precision Medicine And Insurance IPOs Raise A Combined $902 Million
A handful of IPOs and blank checks priced in the short holiday week, led by two sizable issuers. Two smaller IPOs also priced this past week. One IPO is currently scheduled to list in the week ahead, although some small names may also join the calendar throughout the week.
Positive
Seeking Alpha
1 month ago
Caris Life Sciences: Momentum Returns In The IPO Market
Caris Life Sciences is experiencing rapid growth, leveraging AI and molecular science for personalized medicine, but remains deeply unprofitable despite narrowing losses. The IPO was strong, with shares surging post-offering and the company now trading at a steep 15-16x sales multiple, reflecting high investor expectations. While revenue growth is impressive and losses are shrinking, the valuation is too rich for my taste, given the ongoing substantial losses and business risks.
Neutral
Fast Company
1 month ago
Caris Life Sciences IPO: All eyes on the stock price today as the AI cancer care firm makes its Nasdaq debut
On Wednesday morning, the cancer diagnostics biotech firm Caris Life Sciences rang Nasdaq's opening bell in New York, marking the company's awaited initial public offering.
Positive
Market Watch
1 month ago
This ‘AI TechBio' company goes public as IPO demand spreads to biotech
Shares of Caris Life Sciences soared in their public debut Wednesday, as investors bought into the company's business of molecular profiling and drug research using artificial intelligence.
Positive
Market Watch
1 month ago
Caris Life Sciences Shares Rise Following IPO
The biotechnology company started trading at $27 each on Wednesday afternoon, a day after the company's IPO was priced at $21 a share. The stock was recently up 26% and trading at $26.48.
Charts implemented using Lightweight Charts™